You have 9 free searches left this month | for more free features.

CD7CAR

Showing 76 - 100 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023

Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)

Completed
  • Acute Lymphoblastic Leukemia
  • CAR-NK-CD19 Cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Nov 24, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous

Suspended
  • B Cell Lymphoma
  • +2 more
  • Stanford, California
    Stanford Medical Center
Sep 8, 2022

Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023

B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent Trial in Maywood (Fludarabine,

Active, not recruiting
  • B-Cell Acute Lymphoblastic Leukemia, Adult
  • +2 more
  • Maywood, Illinois
    Loyola University
Aug 11, 2022

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

RRMM Trial in Lishui, Wenzhou (CAR-T therapy in Relapsed/Refractory multiple myeloma)

Unknown status
  • RRMM
  • CAR-T therapy in Relapsed/Refractory multiple myeloma
  • Lishui, Zhejiang, China
  • +2 more
Nov 16, 2020

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Langerhans Cell Histiocytosis Trial in Beijing (CD207 CAR-T cells)

Not yet recruiting
  • Langerhans Cell Histiocytosis
  • CD207 CAR-T cells
  • Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Jul 25, 2022

Acute Myeloid Leukemia Trial in Fuzhou (CLL1/+CD33 CAR-T)

Not yet recruiting
  • Acute Myeloid Leukemia
  • CLL1/+CD33 CAR-T
  • Fuzhou, Fujian, China
    Fujian Provincial Children's Hospital
Jul 10, 2023

Myasthenia Gravis Trial in Hangzhou (CD19 CAR-T cells injection)

Recruiting
  • Myasthenia Gravis
  • CD19 CAR-T cells injection
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2023

Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Metabolically Armed CD19 CAR-T cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023

B-cell Non-Hodgkin's Lymphoma Trial in Shanghai (Human CD19Targeted T Cells Injection)

Recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • Human CD19Targeted T Cells Injection
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jun 29, 2022

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Neuromyelitis Optica Trial in Hangzhou (CD19 CAR-T cells injection)

Recruiting
  • Neuromyelitis Optica
  • CD19 CAR-T cells injection
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2023

Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Recruiting
  • Acute Myeloid Leukemia
  • CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)

Not yet recruiting
  • Hematological Malignancy
  • Fludarabine Phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

CAR-T Trial in Hangzhou (GC012F injection)

Recruiting
  • CAR-T
  • GC012F injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
May 10, 2023

Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)

Not yet recruiting
  • Glioblastoma Multiforme of Brain
  • CHM-1101 CAR-T cells
  • Duarte, California
    City of Hope Medical Center
Dec 19, 2022

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Anti-CD33 CAR

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Anti-CD33 CAR T-cells
  • Lymphodepletion Therapy
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023